We are pleased to invite investors and analysts to participate in our virtual event on Tuesday, 16 February, 2021, highlighting Roche data presented at the virtual Angiogenesis, Exudation, and Degeneration 2021 Meeting, from 12th to 13th February.
16:30 – 17:30 CET / 15:30 - 16:30 GMT
10:30 – 11:30 am EST / 7:30 – 8:30 am PST
The webinar will start with a presentation, followed by a Q&A session (live access to the speakers).
Agenda:
Welcome
Karl Mahler, Head of Investor Relations and Roche Group Planning
Ophthalmology Strategy Update
Atul Dandekar, Vice President and Global Franchise Head of Ophthalmology Product Strategy
Ophthalmology Pipeline Update
Christopher Brittain, Vice President and Global Head of Ophthalmology Product Development Faricimab in DME and nAMD – Phase III results Nancy Holekamp, M.D., Retina Specialist and Clinical Investigator
Q&A
Access to virtual event (pre-registration required)
Please pre-register for our webinar here*.
Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.
A replay of the event will be available via ir.roche.com
| Best regards, | |
|
Karl Mahler |
Lisa Tuomi Investor Relations Officer |
| Roche Investor Relations | |
| Dr. Karl Mahler Phone: +41 61 68-78503 e-mail: karl.mahler@roche.com |
Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com |
| Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com |
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com |
| Dr. Gerard Tobin Phone: +41 61 68-72942 e-mail: gerard.tobin@roche.com |
Jon Kaspar Bayard Phone: +41 61 68-83894 e-mail: jon_kaspar.bayard@roche.com |
| Investor Relations North America | |
| Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com |
Dr. Lisa Tuomi Phone: +1 650 467 8737 e-mail: tuomi.lisa@gene.com |
get the latest news and updates to your inbox.